Target Name: SLC2A13
NCBI ID: G114134
Review Report on SLC2A13 Target / Biomarker Content of Review Report on SLC2A13 Target / Biomarker
SLC2A13
Other Name(s): h(+)-myo-inositol cotransporter | Solute carrier family 2 member 13 | MGC48624 | H(+)-myo-inositol symporter | solute carrier family 2 (facilitated glucose transporter), member 13 | solute carrier family 2 member 13 | Proton (H+) myo-inositol symporter | HMIT | H(+)-myo-inositol cotransporter | Hmit | proton (H+) myo-inositol symporter | MYCT_HUMAN | Proton myo-inositol cotransporter

SLC2A13: A Protein Involved in Brain Inositol Transport and Regulation

SLC2A13 is a protein that is expressed in the brain and is involved in the transport of a molecule called inositol. Inositol is a signaling molecule that plays a role in various physiological processes in the body, including mood regulation, insulin sensitivity, and neural function. The transport of inositol across the brain is critical for maintaining the proper levels of this molecule in the brain and for maintaining the normal function of the brain.

SLC2A13 is a member of a family of proteins called the H+-ATP-Ca2+-dependent cotransporters, which are a type of transporter protein that is involved in the transport of a variety of different molecules across the membrane of the cell. These proteins use a specific type of transport mechanism, called ATP-dependent transport, to transport the molecules across the membrane.

SLC2A13 is expressed in the brain and is involved in the transport of inositol across the blood-brain barrier. Inositol is an important molecule that plays a role in the regulation of various physiological processes in the brain, including mood regulation, insulin sensitivity, and neural function. The levels of inositol in the brain are critical for maintaining the proper functioning of the brain and for ensuring the normal growth and development of the brain.

SLC2A13 is also involved in the regulation of the release of other molecules from the brain, including neurotransmitters such as dopamine and serotonin. These molecules are important for various physiological processes in the brain, including mood regulation, movement, and learning. The regulation of the release of these molecules from the brain is critical for maintaining the proper functioning of the brain and for ensuring the normal growth and development of the brain.

SLC2A13 is also involved in the regulation of the attachment of other molecules to the brain surface. This is important for the regulation of the growth and development of the brain and for the maintenance of the normal functioning of the brain. The attachment of other molecules to the brain surface is critical for the regulation of various physiological processes in the brain, including cell signaling, neurotransmission, and mood regulation.

In conclusion, SLC2A13 is a protein that is involved in the transport of inositol across the brain and is critical for the proper functioning of the brain. The regulation of inositol levels in the brain is important for maintaining the normal growth and development of the brain and for ensuring the proper functioning of the brain. SLC2A13 is also involved in the regulation of the release of other molecules from the brain and in the regulation of the attachment of other molecules to the brain surface. These functions make SLC2A13 an attractive drug target and a potential biomarker for the treatment of various neurological and psychiatric disorders.

Protein Name: Solute Carrier Family 2 Member 13

Functions: H(+)-myo-inositol cotransporter (PubMed:11500374). Can also transport related stereoisomers (PubMed:11500374)

The "SLC2A13 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC2A13 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

SLC2A14 | SLC2A2 | SLC2A3 | SLC2A3P1 | SLC2A4 | SLC2A4RG | SLC2A5 | SLC2A6 | SLC2A7 | SLC2A8 | SLC2A9 | SLC2A9-AS1 | SLC30A1 | SLC30A10 | SLC30A2 | SLC30A3 | SLC30A4 | SLC30A4-AS1 | SLC30A5 | SLC30A6 | SLC30A7 | SLC30A8 | SLC30A9 | SLC31A1 | SLC31A2 | SLC32A1 | SLC33A1 | SLC34A1 | SLC34A2 | SLC34A3 | SLC35A1 | SLC35A2 | SLC35A3 | SLC35A4 | SLC35A5 | SLC35B1 | SLC35B2 | SLC35B3 | SLC35B4 | SLC35C1 | SLC35C2 | SLC35D1 | SLC35D2 | SLC35D3 | SLC35E1 | SLC35E1P1 | SLC35E2A | SLC35E2B | SLC35E3 | SLC35E4 | SLC35F1 | SLC35F2 | SLC35F3 | SLC35F4 | SLC35F5 | SLC35F6 | SLC35G1 | SLC35G2 | SLC35G3 | SLC35G4 | SLC35G5 | SLC35G6 | SLC36A1 | SLC36A2 | SLC36A3 | SLC36A4 | SLC37A1 | SLC37A2 | SLC37A3 | SLC37A4 | SLC38A1 | SLC38A10 | SLC38A11 | SLC38A2 | SLC38A3 | SLC38A4 | SLC38A4-AS1 | SLC38A5 | SLC38A6 | SLC38A7 | SLC38A8 | SLC38A9 | SLC39A1 | SLC39A10 | SLC39A11 | SLC39A12 | SLC39A13 | SLC39A14 | SLC39A2 | SLC39A3 | SLC39A4 | SLC39A5 | SLC39A6 | SLC39A7 | SLC39A8 | SLC39A9 | SLC3A1 | SLC3A2 | SLC40A1 | SLC41A1